Novo Nordisk A/S (NVO): Degludecplus Provides Superior Glycaemic Control Compared to Insulin Glargine in a Phase 3a Trial in Japanese People with Type 2 Diabetes  
11/7/2011 8:53:21 AM

BAGSVAERD, DENMARK--(Marketwire - November 07, 2011) -

Company Announcement no 70 / 2011:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information


Katrine Sperling
Tel: (+45) 4442 6718
Email Contact

In North America:
Ambre Morley
Tel: (+1) 609 216 5240
Email Contact

Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact